These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 16829767)
21. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569 [TBL] [Abstract][Full Text] [Related]
22. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report]. Macioszek A; Baczyk M; Kopeć T; Sowiński J Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451 [TBL] [Abstract][Full Text] [Related]
23. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741 [TBL] [Abstract][Full Text] [Related]
25. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging. Jentzen W; Richter M; Nagarajah J; Poeppel TD; Brandau W; Dawes C; Bockisch A; Binse I EJNMMI Phys; 2014 Dec; 1(1):100. PubMed ID: 26501458 [TBL] [Abstract][Full Text] [Related]
26. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534 [TBL] [Abstract][Full Text] [Related]
27. Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands. Nabaa B; Takahashi K; Sasaki T; Okizaki A; Aburano T AJNR Am J Neuroradiol; 2012 Nov; 33(10):1964-70. PubMed ID: 22555571 [TBL] [Abstract][Full Text] [Related]
28. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. Sgouros G; Song H; Ladenson PW; Wahl RL J Nucl Med; 2006 Dec; 47(12):1977-84. PubMed ID: 17138740 [TBL] [Abstract][Full Text] [Related]
29. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? Fallahi B; Beiki D; Abedi SM; Saghari M; Fard-Esfahani A; Akhzari F; Mokarami B; Eftekhari M Nucl Med Commun; 2013 Aug; 34(8):777-86. PubMed ID: 23708871 [TBL] [Abstract][Full Text] [Related]
30. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357 [TBL] [Abstract][Full Text] [Related]
31. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139 [TBL] [Abstract][Full Text] [Related]
32. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Caglar M; Tuncel M; Alpar R Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122 [TBL] [Abstract][Full Text] [Related]
33. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy]. Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904 [TBL] [Abstract][Full Text] [Related]
34. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273 [TBL] [Abstract][Full Text] [Related]
35. Salivary gland protection with sialagogues: a case study. Van Nostrand D; Atkins F; Bandaru VV; Chennupati SP; Moreau S; Burman K; Wartofsky L Thyroid; 2009 Sep; 19(9):1005-8. PubMed ID: 19500022 [TBL] [Abstract][Full Text] [Related]
36. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. Corrêa NL; de Sá LV; de Mello RC Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670 [TBL] [Abstract][Full Text] [Related]
37. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial. Upadhyaya A; Zhou P; Meng Z; Wang P; Zhang G; Jia Q; Tan J; Li X; Hu T; Liu N; Wang S; Liu X; Wang H; Zhang C; Zhao F; Yan Z; Wang X; Zhang X; Zhang W Nucl Med Commun; 2017 Nov; 38(11):891-903. PubMed ID: 28806348 [TBL] [Abstract][Full Text] [Related]
38. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods. Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171 [TBL] [Abstract][Full Text] [Related]
39. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model. Bohuslavizki KH; Klutmann S; Jenicke L; Brenner W; Feyerabend B; Henze E; Clausen M Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):181-6. PubMed ID: 10477022 [TBL] [Abstract][Full Text] [Related]
40. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study. Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]